{"nctId":"NCT00291187","briefTitle":"VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia","startDateStruct":{"date":"2006-02"},"conditions":["Insomnia"],"count":411,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"20 mg VEC-162","type":"EXPERIMENTAL","interventionNames":["Drug: 20 mg VEC-162"]},{"label":"50 mg VEC-162","type":"EXPERIMENTAL","interventionNames":["Drug: 50 mg VEC-162"]},{"label":"100 mg VEC-162","type":"EXPERIMENTAL","interventionNames":["Drug: 100 mg VEC-162"]}],"interventions":[{"name":"20 mg VEC-162","otherNames":[]},{"name":"50 mg VEC-162","otherNames":[]},{"name":"100 mg VEC-162","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy subjects with no medical, psychiatric or current sleep disorders.\n* Subject must sign a written consent form.\n\nExclusion Criteria:\n\n* Recent history of night shift work or jet lag.\n* Prior experience sleeping in a sleep lab environment.\n* History of sleep disorders.","healthyVolunteers":true,"sex":"ALL","minimumAge":"21 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Improvement of Latency to Persistent Sleep (LPS)","description":"The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.8","spread":"4.28"},{"groupId":"OG001","value":"24.3","spread":"4.35"},{"groupId":"OG002","value":"19.6","spread":"4.31"},{"groupId":"OG003","value":"23.1","spread":"4.21"}]}]}]},{"type":"SECONDARY","title":"Average Improvement of Wake After Sleep Onset (WASO)","description":"The average improvement of wake after sleep onset (time spent awake between onset of sleep and lights on, determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139.3","spread":"7.33"},{"groupId":"OG001","value":"115.1","spread":"7.46"},{"groupId":"OG002","value":"105.6","spread":"7.39"},{"groupId":"OG003","value":"121.9","spread":"7.22"}]}]}]},{"type":"POST_HOC","title":"Average Improvement in Total Sleep Time (TST)","description":"The average improvement in Total sleep time (determined by PSG and defined as the number of non-wake minutes between lights off and lights on) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"317.6","spread":"7.65"},{"groupId":"OG001","value":"351.4","spread":"7.78"},{"groupId":"OG002","value":"365.5","spread":"7.71"},{"groupId":"OG003","value":"347.2","spread":"7.53"}]}]}]},{"type":"POST_HOC","title":"Average Improvement in Latency to Non-awake (LNA)","description":"The average improvement in latency to non-awake (length of time elapsed between lights off and first epoch of sleep determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":"2.88"},{"groupId":"OG001","value":"11.2","spread":"2.93"},{"groupId":"OG002","value":"8.0","spread":"2.90"},{"groupId":"OG003","value":"10.0","spread":"2.84"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":103},"commonTop":["Nausea","Headache","Abnormal Dreams","Dry Mouth","Dyspepsia"]}}}